Frank A. Sinicrope, MD, on Adjuvant Treatment Strategies for Stage III dMMR Colon Cancer
2025 ASCO Annual Meeting
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ATOMIC was for patients with deficient mismatch repair stage 3 colon cancer. All of these patients had undergone a surgical resection with curative intent and all were found to have deficient mismatch repair tumors by immunohistochemistry. Patients were randomized 1 to 1 to FOLFOX chemotherapy plus atezolizumab given for six months, with the atezolizumab continued for an additional six months. This was compared to FOLFOX alone for six months. Atezolizumab, as we know, is an anti–PD-L1 antibody. The objective of this study was to see whether or not the immunotherapy would improve outcomes compared to chemotherapy alone. At the second interim analysis of this trial, with 75% of events, the trial was stopped. The results were reported out at a median follow-up of 37.2 months. The chemoimmunotherapy was associated with a hazard ratio of 0.5, indicating that there was a reduction in recurrence or death by 50% compared to the FOLFOX arm. So these are impressive results we regard as practice-changing, and I would comment that the treatments were well tolerated and not associated with really any adverse events that would not be expected with each of the agents. So we regard this treatment as a new standard of care for this patient population, and it really demonstrates that taking immunotherapy that we're commonly using in this population in the metastatic setting now can be moved to earlier-stage or stage 3 disease to benefit these patients also. So we think this is a very clinically meaningful result for patients, and we're very excited to continue to see if the guidelines will now be adopting this new regimen for our patients.
The ASCO Post Staff
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011).
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, reviews the final analysis of phase II CAPTIVATE study demonstrating the long-term efficacy and safety of ibrutinib plus venetoclax for previously untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including in patients with high-risk genomic features. The 5.5-year progression-free survival and overall survival rates were 66% and 97%, respectively (Abstract 7036).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500).
The ASCO Post Staff
Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504).
The ASCO Post Staff
Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510).